## BDX: Becton, Dickinson and Company - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.01 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: declining volume (55% of avg), momentum weakening (-2.8% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($185.43)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 0)

**1. There May Be Reason For Hope In Becton Dickinson's (NYSE:BDX) Disappointing Earnings**
- Source: Yahoo Finance Singapore | 20251203T140200 | Somewhat-Bullish | Relevance: 100%
- Becton Dickinson's recent weak earnings may be understated due to a significant impact from unusual items totalling US$1.3 billion, which are often one-off in nature. If these expenses don't recur, the company's profitability is expected to improve in the next year. The article suggests that Becton Dickinson's statutory profit likely understates its true earnings potential, especially given a 7.6% annual EPS growth over the last three years.

**2. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: PR Newswire | 20251203T115000 | Bullish | Relevance: 100%
- BD (Becton, Dickinson and Company) announced the global commercial release of new configurations for its BD FACSDiscover™ A8 Cell Analyzers. These new three- and four-laser instruments expand accessibility to breakthrough spectral and real-time imaging cell analysis, enabling more labs in academia, pharma, and biotech to advance discoveries in immunology, cancer immunotherapy, and cell biology. The analyzers feature BD SpectralFX™ Technology for analyzing 50+ cell characteristics and BD CellView™ Image Technology for high-speed imaging, with flexible upgrade options and financing available.

**3. BD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes**
- Source: BD Newsroom | 20251203T101255 | Bullish | Relevance: 100%
- BD has globally released new configurations of its FACSDiscover A8 Cell Analyzers, featuring BD SpectralFX and BD CellView Image technologies. These additions, including three- and four-laser options, aim to make cutting-edge spectral and real-time imaging cell analysis more accessible to academic, pharma, and biotech labs of all sizes and budgets. The technology enhances discovery in immunology, cancer immunotherapy, and cell biology by allowing analysis of up to 50 cellular characteristics and providing real-time spatial and morphological insights.

**4. BD Launches Portable PureWick Device to Help Women Manage Urinary Incontinence on the Go**
- Source: The Healthcare Technology Report. | 20251201T132120 | Bullish | Relevance: 100%
- BD has expanded its PureWick™ portfolio with a new portable urine collection system for individuals managing urinary incontinence, particularly wheelchair users, offering greater flexibility outside the home. The battery-powered device utilizes external suction technology in a lightweight, mobile form factor with up to eight hours of battery life. This innovation aims to enhance confidence and independence by providing a discreet, accessible solution for managing incontinence in daily activities and travel.

**5. Is Becton, Dickinson and Company Stock Underperforming the Nasdaq?**
- Source: Markets Financial Content | 20251201T092900 | Neutral | Relevance: 100%
- Becton, Dickinson and Company (BDX) has underperformed the Nasdaq Composite, with its stock slipping 23% from its 52-week high and showing weaker gains over three months, YTD, and the past 52 weeks. Despite this, the company's Q4 results exceeded EPS expectations, and analysts maintain a "Moderate Buy" rating with a potential upside. BDX's underperformance is attributed to macro challenges, including vaccine demand and biosciences research headwinds.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $210 | $197 | +7% |
| 2025-11-07 | RBC Capital | $202 | $211 | -4% |
| 2025-11-07 | Piper Sandler | $190 | $200 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |
| 2025-11-07 | RBC Capital | main | Sector Perform |
| 2025-11-07 | Piper Sandler | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($0.04M) |
| Sells | 5 ($0.06M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (+0.5%)
- Blackrock Inc.: 9.7% (+1.7%)
- T. Rowe Price Invest: 5.7% (+0.3%)
- State Street Corpora: 4.9% (+3.4%)
- JPMORGAN CHASE & CO: 3.7% (+132.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.01 suggests fair value with growth premium. Balance sheet: $2.7B free cash flow. Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $56.0B |
| Beta | 0.28 |
| 52W Range | $162.29 - $251.99 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.01 |
| Forward P/E | 12.2 |
| Current P/E | 13.0 |
| YoY Growth | 6.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 3.1% to 0.3% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 (-0.1%) diverging from MRS_20 - short-term weakness emerging. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. Volume at 55% of 20MA suggests lack of conviction. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.28% (CS: 54) | Neutral |
| RSI_14 | 57.5 | Neutral |
| MACD Histogram | 0.21 | Bullish |
| vs SMA20 | 1.022x | Above |
| vs SMA50 | 1.031x | Above |
| vs SMA200 | 1.010x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $193.57
- **Stop Loss:** $185.43 (4.2% risk)
- **Target:** $209.85 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 116
- **Position Value:** $22,454.12
- **Portfolio %:** 22.45%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-09 (Est: $2.81)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.91 | $3.96 | +1.1% |
| 2025Q2 | $3.40 | $3.68 | +8.2% |
| 2025Q1 | $3.28 | $3.35 | +2.1% |
| 2024Q4 | $2.99 | $3.43 | +14.7% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*